¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"growth form"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • growth phase
    Áõ½Ä±â
  • growth plate
    ¼ºÀåÆÇ
  • growth quotient
    ¼ºÀåÁö¼ö, ¹ßÀ°Áö¼ö
  • growth rate
    ¼ºÀå·ü
  • growth rate constant
    Áõ½Ä·ü»ó¼ö
  • growth recovery line
    ¼ºÀåȸº¹¼±
  • growth regulator
    ¼ºÀåÁ¶ÀýÀÎÀÚ
  • growth retardation
    ¹ßÀ°Áö¿¬, ¼ºÀåÁö¿¬
  • growth spurt
    ¼ºÀå±ÞÁõ
  • growth zone
    ¼ºÀ屸¿ª, ¼ºÀå´ë
  • growth-onset diabetes
    ¹ßÀ°±â¹ßº´´ç´¢º´, Ãʱâ´ç´¢º´
  • hematopoietic growth factor
    Ç÷¾×Çü¼º¼ºÀåÀÎÀÚ, Á¶Ç÷¼ºÀåÀÎÀÚ
  • intrauterine growth restriction
    Àڱ󻼺ÀåÁ¦ÇÑ
  • intrauterine growth retardation
    Àڱ󻼺ÀåÁö¿¬
  • isometric growth
    µîÀ强¼ºÀå
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • transforming growth factor
    Àüȯ¼ºÀåÀÎÀÚ
  • vascular endothelial growth factor
    Ç÷°ü³»ÇǼºÀåÀÎÀÚ
  • growth
    ¼ºÀå, Áõ½Ä
  • growth hormone
    ¼ºÀåÈ£¸£¸ó
  • growth inducer
    ¼ºÀåÀ¯¹ßÀÎÀÚ
  • growth line
    ¼ºÀå¼±
  • growth pattern
    ¼ºÀå¾ç½Ä
  • growth period
    ¼ºÀå±â°£
  • growth phase
    Áõ½Ä±â
  • growth plate
    (¢¡epiphyseal cartilage) »À³¡¿¬°ñ
  • growth quotient
    ¼ºÀåÁö¼ö, ¹ßÀ°Áö¼ö
  • growth rate
    ¼ºÀå·ü
  • growth regulator
    ¼ºÀåÁ¶ÀýÀÎÀÚ
  • growth zone
    ¼ºÀ屸¿ª
  • growth arrest line
    ¼ºÀåÁ¤Áö¼±
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • growth constant
    ¼ºÀå»ó¼ö(ÊÙË×Ëà).
  • growth curvature
    ¼ºÀå°î¼±(ÊÙË­ËÛ).
  • growth curvature
    ¼ºÀå°î¼±(¡­ÍØàÊ).
  • growth curve
    Áõ½Ä°î¼±, ¼ºÀå°î¼±.
  • growth curve
    Áõ½Ä°î¼±
  • growth curve, one-step
    ÀÏȸÁõ½Ä°î¼±
  • growth curve, single-step
    ÀÏȸÁõ½Ä°î¼±
  • growth cycle
    Áõ½ÄÁÖ±â
  • growth defect
    ¼ºÀå°áÇÔ
  • growth delay
    ¼ºÀåÁö¿¬
  • growth factor
    ¼ºÀå ÀÎÀÚ
  • growth factor
    ¼ºÀåÀÎÀÚ(à÷íþì×í­).
  • growth factor
    Áõ½ÄÀÎÀÚ
  • growth factor
    ¼ºÀå ÀÎÀÚ(à÷íþ ì×í­)
  • growth factor, B cell (BCGF)
    B¼¼Æ÷ Áõ½ÄÃËÁøÀÎÀÚ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • rough form
    RÇü(¡­úþ).
  • stable L-form
    ¾ÈÁ¤µÈ L-Çü[¼¼]±Õ
  • star form
    º°Çü(ÊÙÌ´).
  • subperiodic form
    ÁØÁÖ±âÇü(ñÞñÎÑ¢û¡).
  • subperiodic form
    ÁØÁÖ±âÇü(ñÞñÎÑ¢û¡)
  • tissue form
    Á¶Á÷Çü
  • tissue form
    Á¶Á÷Çü(ðÚòÄû¡)
  • transitional form
    ÀÌÇàÇü(ì¹ú¼û¡)
  • undercut form
    ÷¿ÍÇüÅÂ(ôÕèÀû¡÷¾).
  • undissociated form
    ºñÇØ¸®Çü.
  • variant form
    ÀÌÇü(ì¶úþ).
  • variant form
    ÀÌÇü(ì¶úþ)
  • variations of form
    Çüź¯ÀÌ
  • vegetative form
    ¿µ¾çÇü(ç½å×û¡).
  • vegetative form
    ¿µ¾çÇü(ç½å×û¡).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • tail growth
    ²¿¸®¼ºÀå (à÷íþ)
  • tailward growth
    ²¿¸®¹æÇâ ¼ºÀå (à÷íþ)
  • T cell growth factor
    T ¼¼Æ÷¼ºÀåÀÎÀÚ (á¬øàà÷íþì×í­)
  • transforming growth factor
    º¯Çü ¼ºÀå ÀÎÀÚ(ܨû¡à÷íþ ì×í­)
  • unbalanced growth
    ºÒ±ÕÇü(ÝÕгû¬) ¼ºÀå (à÷íþ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
CRF case report form; chronic renal failure; chronic respiratory failure; coagulase-reacting factor; con...
CTMM-SF California Test of Mental Maturity-Short Form
CWDF cell wall-deficient form [bacteria]
CWF Cornell Word Form
DRF Daily Rating Form; daily replacement factor; Deafness Research Foundation; dose reduction factor
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
GST-P+ glutathione S-transferase placental form positive
iNOS inducible form of .NO synthase
iNOS inducible form of NOS
iNOS inducible form of nitric oxide synthase
sCD14 soluble form of CD14
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • box-form
    »óÇü ¿Íµ¿ÀÇ
  • chemical form
    È­ÇÐÀû Çü»ó
  • circumscribed form
    ±¹ÇѼº ÇüÅÂ
  • color form sorting test
    »öä ÇüÅ Ã߸®±â °Ë»ç
  • convenience form
    ÆíÀÇ ÇüÅÂ
    ÃæÀü¿¡ ÇÊ¿¬ÀûÀÎ ±âº»ÀûÀÎ ¿Íµ¿ÀÇ ÇüÅ·μ­ ¿Íµ¿Àº ¾ðÁ¦³ª ¸ðµç ÃæÀü Á¶ÀÛ¿¡ À־ ±× Á¶ÀÛÀ» ÆíÇÏ°Ô ÇÒ ¼ö ÀÖ´Â ÀûÀýÇÑ ÇüÅ·Π¿Íµ¿À» Çü¼ºÇÏ´Â °Í.
  • crescent form
    ¹Ý´ÞÇü, ¹Ý¿ùü, ¹Ý¿ùÇü
  • facial form
    ¾È¸ð
  • form-other
    Çü½Ä»óÀÇ ¸ñ
  • initial form
    Ãʱâ ÇüÅÂ
  • L-form
    L-Çü
  • large surface form
    ³ÐÀº ¸éÀÇ ÇüÅÂ
  • lethal form
    Ä¡»çÀûÀÎ ÇüÅÂ
  • liquid form
    ¾×ü »óÅÂ
    ¹°À̳ª ±â¸§°ú °°ÀÌ ÀÚÀ¯·ÎÀÌ À¯µ¿ÇÏ¿© ¿ë±âÀÇ ¸ð¾ç¿¡ µû¶ó ±× ¸ð¾çÀÌ º¯Çϸç ÀÏÁ¤ÇÑ ÇüŸ¦ °¡ÁöÁö ¾Ê°í ¾ÐÃàÇØµµ °ÅÀÇ ºÎÇǰ¡ º¯ÇÏÁö ¾Ê´Â ¹°Áú. Á¤È®È÷´Â ¾×ü »óŶó°í ÇÑ´Ù. ¼ö¸¹Àº ¹°Áú °¡¿îµ¥ »ó¿Â, »ó¾Ð¿¡¼­ ÀÌ¿Í °°Àº »óŸ¦ °¡Áö´Â °ÍÀº ºñ±³Àû ÀûÀ¸³ª, Àû´çÇÑ ¿Âµµ¿Í ¾Ð·ÂÀÇ Á¶°ÇÀÌ °®Ãß¾îÁö¸é °ÅÀÇ ¸ðµç ¹°ÁúÀÌ ¾×ü·Î º¯ÇÒ ¼ö ÀÖÀ¸¸ç, ¹Ý´ë·Î ¾×üµµ ´Ù½Ã ±âü³ª °íü·Î º¯ÇÒ ¼ö ÀÖ´Ù. Áï, ¾×ü¶ó´Â °ÍÀº ¹°Áú¿¡ °íÀ¯ÇÑ ¼ºÁúÀÌ ¾Æ´Ï¶ó Á¶°Ç¿¡ µû¶ó¼­ ±âü·Îµµ °íü·Îµµ º¯ÇÒ ¼ö ÀÖ´Â ¹°ÁúÀÇ Á¸Àç »óÅÂÀÇ Çϳª¿¡ ºÒ°úÇÏ´Ù. ÀÌ·± ¶æ¿¡¼­ °íü»ó, ±âü»ó¿¡ ´ëÇØ¼­ ¾×ü»óÀ̶ó°í ÇÏ´Â °æ¿ìµµ ÀÖ´Ù. ¶ÇÇÑ ÇϳªÀÇ ¹°ÁúÀÌ °íü¿¡¼­ ¾×ü·Î º¯È­ÇÏ´Â Çö»óÀ» À¶ÇØ, ¾×ü¸é¿¡¼­ ±âÈ­ÇÏ´Â °ÍÀ» Áõ¹ßÀ̶ó°í Çϳª, ±âÈ­´Â ¾×ü ³»ºÎ¿¡¼­µµ ÀϾ¸ç, ¾×ü°¡ Àü¸éÀûÀ¸·Î ±âü·Î º¯ÇÏ´Â Çö»óÀ» ºñµîÀ̶ó°í ÇÑ´Ù. ÀÏÁ¤ÇÑ ¾Ð·ÂÇÏ¿¡¼­ÀÇ
  • localized form
    ±¹¼Ò Çü
  • marginal form
    ¿Ü¿¬ ÇüÅÂ, º¯¿¬ ÇüÅÂ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
receptors, platelet-derived growth factor Specific molecular sites or structures on cell membranes that react with platelet-derived growth factor, its analogs, or antagonists, to elicit or to inhibit the specific response of the cell to this factor. Pdgf binds with different affinities and specificities to two structurally related receptors, the alpha-receptor and the beta-receptor. Both of these receptors are transmembrane proteins with an intracellular, ligand-stimulatable protein kinase domain.
(12 Dec 1998)
receptors, transforming growth factor beta Cell-surface proteins that bind transforming growth factor beta and trigger changes influencing the behaviour of cells. Two types of transforming growth factor receptors have been recognised. They differ in affinity for different members of the transforming growth factor beta family and in cellular mechanisms of action. Transforming growth factor alpha binds to the same receptors as epidermal growth factor (see receptors, epidermal growth factor-urogastrone).
(12 Dec 1998)
vertical growth phase Spread of melanoma cells from the epidermis into the dermis and later the subcutis, from which site metastasis may take place.
(05 Mar 2000)
cell growth <cell biology> Usually used to mean increase in the size of a population of cells though strictly should be reserved for an increase in cytoplasmic volume of an individual cell.
(26 Mar 1998)
melanoma growth stimulatory activity Cytokine of the C X C subfamily. Potent mitogen. Activates and is chemotactic for, neutrophils.
(18 Nov 1997)
personal growth laboratory A sensitivity training setting in which the primary emphasis is on each participant's potentialities for creativity, empathy, and leadership.
See: sensitivity training group.
(05 Mar 2000)
growth 1. The process of growing; the gradual increase of an animal or a vegetable body; the development from a seed, germ, or root, to full size or maturity; increase in size, number, frequency, strength, etc.; augmentation; advancement; production; prevalence or influence; as, the growth of trade; the growth of power; the growth of intemperance. Idle weeds are fast in growth.
2. That which has grown or is growing; anything produced; product; consequence; effect; result. "Nature multiplies her fertile growth." (Milton)
Origin: Icel. Gror, gri. See Grow.
Source: Websters Dictionary
(01 Mar 1998)
growth and embryonic development Developmental processes from cell division to embryogenesis to postnatal growth and maturity.
(12 Dec 1998)
growth arrest lines Dense lines parallel to the growth plates of long bones on radiographs, representing temporary slowing or cessation of longitudinal growth.
Synonym: Harris' lines.
(05 Mar 2000)
growth associated proteins <growth factor> Group of developmentally regulated polypeptides thought to be critical for the formation of neural circuitry. The acidic membrane phosphoprotein GAP 43 is synthesised and transported down regenerating and developing axons, pp46 localised in growth cone membranes during embryogenesis, B 50 in mature presynaptic membranes in the regulation of phosphotidylinositol turnover and F1 in the hippocampus during long-term potentiation, are now all known to be the same protein.
(18 Nov 1997)
growth cone <cell biology> A specialised region at the tip of a growing neurite that is responsible for sensing the local environment and moving toward the neuron's target cell. Growth cones are hand shaped, with several long filopodia that differentially adhere to surfaces in the embryo. Growth cones can be sensitive to several guidance cues, for example: surface adhesiveness, growth factors, neurotransmitters and electric fields (galvanotropism).
(18 Nov 1997)
growth cone collapse <cell biology> Loss of motile activity and cessation of advance by growth cones. There are now thought to be specific molecules that inhibit the motility of particular growth cones and are important in establishing correct pathways in developing nervous systems.
See: axon pathfinding.
(18 Nov 1997)
growth control <cell biology> When applied to cells usually means control of growth of the population, i.e. Of the rate of division rather than of the size of an individual cell.
(18 Nov 1997)
growth curve A graphic representation of the change in size of an individual or a population over a period of time.
(05 Mar 2000)
growth disorders Deviations from the average values for a specific age and sex in any or all of the following: height, weight, skeletal proportions, osseous development, or maturation of features. The concept includes both acceleration and retardation of growth.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
ÅëÇÕ°Ë»ö ¿Ï·á